Table 6.
Comparison of Clinical Characteristics Between the Patients with and without Respiratory Symptoms Worsening
| Respiratory Symptoms Worsening | P-value | ||
|---|---|---|---|
| No (n = 108) | Yes (n = 45) | ||
| Age (years) | 71.8 ± 9.6 | 72.5 ±10.6 | 0.679 |
| Male | 94 (87.0) | 36 (80.0) | 0.267 |
| BMI (kg/m2) | 23.4 ± 2.87 | 22.9 ± 3.3 | 0.312 |
| Smoking status | |||
| Never-smoker | 21 (19.4) | 11 (24.4) | 0.301 |
| Ex-smoker | 58 (53.7) | 18 (40.0) | |
| Current-smoker | 29 (26.9) | 16 (35.6) | |
| CAT score | |||
| <10 | 91 (85.0) | 26 (57.8) | <0.001 |
| ≥10 | 16 (15.0) | 19 (42.2) | |
| Frequency of exacerbation (/year) | |||
| 0–1 | 106 (98.1) | 40 (88.9) | 0.024 |
| ≥2 | 2 (1.9) | 5 (11.1) | |
| Medications | |||
| SABA | 2 (1.9) | 2 (4.4) | 0.581 |
| SAMA | 1 (0.9) | 1 (2.2) | 0.503 |
| ICS/LABA | 58 (53.7) | 24 (53.3) | 0.967 |
| LAMA | 61 (56.5) | 26 (57.8) | 0.883 |
| Theophylline | 4 (3.7) | 5 (11.1) | 0.125 |
Note: Data are presented as mean ± standard deviation or n (%).
Abbreviations: BMI, body mass index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist.